JP Morgan Maintains Overweight on Relay Therapeutics, Raises Price Target to $31

Benzinga Newsdesk www.benzinga.com Positive 81.3%

Neg 0% Neu 0% Pos 81.3%

JP Morgan analyst Priyanka Grover maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from $28 to $31.